The global opioid use disorder market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rise in the opioid epidemic in the United States, as well as the implementation of government measures to combat the epidemic.
Request Free Sample Report Here
Opioids are chemicals that interact with opioid receptors on nerve cells in the body and brain to manage pain. They can be natural, or synthetic produced in laboratories to replicate the qualities of natural opioids. Prescription pain relievers, synthetic opioids, and heroin all fall within this category. Acute pain such as after an injury or surgery, chronic pain, active-phase cancer therapy, palliative care, and end-of-life care are all conditions for which prescription opioids are recommended. Many patients rely on prescription opioids to help them manage their symptoms while under the supervision of a doctor.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing consumption of opioid due to increasing prevalence of chronic diseases such as cancer, cardiovascular, pain arising from injuries, and other conditions are expected to propel the market growth during the forecast period.
- Increasing initiatives by government and private institutes for curbing the increased consumption of opioids are anticipated to fuel the market growth in the coming years.
- Adverse side effects associated from the administration of drugs for the treatment of opioid addiction is projected to hamper the market growth during the forecast period.
- Lack of awareness and limited product availability presents as key challenges that can hinder the market expansion during the period.
- Increased R&D activities and upcoming product launches are projected to offer lucrative opportunities for the market players.
Market Segment Insights
Buprenorphine segment is expected to account for a key share of the market
Based on drug, the opioid use disorder market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment is further sub segmented into bunavail, sublocade, suboxone, zubsolv, and others. The buprenorphine segment is expected to account for a key share of the market during the forecast period owing to increasing usage of buprenorphine-containing products such as bunavail, sublocade, suboxone, and zubsolv. Suboxone is the most commonly prescribed medicine for the treatment of opioid use disorder, owing to its great effectiveness, few side effects, and advantageous formulary coverage.
North America is anticipated to dominate the market
On the basis of regions, the opioid use disorder market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to presence of key player, favorable initiatives by governments and wide range of product offering by key players. Several initiatives are being implemented by governments to combat the situation. For example, in January 2018, the United States government started a public awareness campaign to tackle opioid addiction.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
